ClinicalTrials.gg
CompletedNCT00582426LARCIDUpdated May 4, 2015Results posted

Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea

A Phase 3 interventional study of Octreotide Long Acting Release and Standard Treatment in Chemotherapy-induced Diarrhea, sponsored by Novartis Pharmaceuticals. Completed at 11 sites in Brazil. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-05-04.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
139
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Colorectal Neoplasms by Novartis — 3 open to participants now, 7 under way, none of them phase 3. Colorectal Neoplasms · Novartis.

Enrollment
13th of 30
139 · median 123
Started
2008
the only one that year
Phase 3
4 of 30
none open now
Registered
8th of 30
by date

Among the 30 studies in Colorectal Neoplasms by Novartis, this one is the 13th largest by enrollment, is the only one that started in 2008, is one of 4 in phase 3, and was the 8th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

3 of the 30 studies in Colorectal Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Colorectal Neoplasms by Novartis, or all of them as a file.
02

Study summary

This study will evaluate the efficacy of Octreotide LAR in preventing chemotherapy-induced diarrhea (with regimens that contain 5 fluorouracil, irinotecan and capecitabine)in patients with colorectal cancer.

Read the detailed description

Eligible patients will have a diagnosis of colorectal cancer, and will be candidates to adjuvant chemotherapy or first-line chemotherapy for metastatic disease with a regimen containing fluorouracil, capecitabine and/or irinotecan. Eligible chemotherapy regimens include Irinotecan, Leucovorin (folinic acid), and Fluorouracil(IFL), Leucovorin, Fluorouracil, and Irinotecan (FOLFIRI), combinations of Irinotecan and Capecitabine, the Roswell Park regimen and the Mayo Clinic regimen, all of them without or with Oxaliplatin, Bevacizumab or Cetuximab. Patients receiving Erlotinib, or other Tyrosine-kinase, Epidermal Growth Factor Receptor (EGFR)-inhibitors, will not be eligible.

The acute treatment for diarrhea will be left to physician's discretion in both groups. Patients in the control arm will be treated without Octreotide LAR. Patients in the experimental arm will receive the first dose of Octreotide LAR (30 mg) at chemotherapy initiation, in addition to a minimum of two more identical monthly doses of Octreotide LAR (with an interval of 28 days between them), until chemotherapy is discontinued or for a maximum of six doses of Octreotide LAR, whichever occurs first. Patient evaluation will be done at each cycle for efficacy and toxicity.

03

Conditions studied

  • Chemotherapy-induced Diarrhea

Keywords

  • Colorectal cancer
  • diarrhea
  • drug therapy
  • octreotide
  • fluorouracil
  • irinotecan
  • capecitabine
  • prevention
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Providing a written
  2. Age between 18 and 80 years;
  3. Histological diagnosis of colorectal cancer, presence of disease and no prior systemic therapy for metastatic disease (prior therapy will be allowed if completed 6 months or longer before inclusion in the study);
  4. Indication of treatment, according to the judgment of the investigator, with a chemotherapy regimen containing either 5-FU, capecitabine, or irinotecan; any such regimen may also include oxaliplatin, bevacizumab, or cetuximab;
  5. A performance status of 0 or 1 according to the (ECOG) scale
  6. Adequate organ function and lab values within specific ranges
  7. Female patients of must have a negative serum pregnancy test within 7 days prior to registration;
  8. Fertile patients (male or female) must agree to use an acceptable method of to avoid pregnancy for the duration of the study and for 3 months after study termination;
  9. No prior use of octreotide in any formulation.

Exclusion criteria

Exclusion criteria:

  1. Use of concomitant antineoplastic treatments, other than regimens containing either 5-FU, capecitabine, or irinotecan with or without oxaliplatin, bevacizumab, or cetuximab;
  2. Previous or concomitant need for radiotherapy to the abdomen or pelvis;
  3. Indication of treatment, according to the judgment of the investigator, with erlotinib, gefitinib, panitumumab, or other EGFR-inhibitors other than cetuximab;
  4. A second (except in situ carcinoma of the cervix, in situ carcinoma of the bladder, adequately treated basal-cell or squamous-cell carcinoma of the skin, or another malignancy treated more than 5 years prior to enrollment and without recurrence);
  5. Any type of condition leading to chronic diarrhea, including, but not limited to inflammatory bowel disease (e.g., ulcerative colitis and Crohn's disease), chronic diarrhea of presumed or confirmed infectious origin, and irritable bowel syndrome;
  6. Active or uncontrolled concurrent medical condition, including, but not limited to, unstable angina, congestive heart failure, coronary artery disease, hypertension, diabetes mellitus, and hyper- or hypothyroidism;
  7. Active and ongoing systemic infection;
  8. Serious uncontrolled psychiatric illness;
  9. Ongoing pregnancy or lactation;
  10. Female patients who are pregnant or lactating, or are of and would not practice a medically acceptable method for ;
  11. Lesions that have been irradiated cannot be included as sites of . If the only measurable lesion was previously irradiated the patient cannot be included;
  12. Use of any agent within 30 days prior to enrollment in the study or foreseen use of an investigational agent during the study;
  13. History of chronic (≥ 30 nonconsecutive days) use of laxatives;
  14. Concurrent use of antidiarrheal agents;
  15. Inability to comply with the study protocol.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    Octreotide Long Acting Release

    Prevention of Chemotherapy Induced Diarrhea (CID)

    Drug: Octreotide Long Acting Release

  • Other
    Standard Treatment

    Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.

    Other: Standard Treatment

Interventions

  • Patients will receive the first dose of Octreotide LAR (30 mg) at chemotherapy initiation, in addition to a minimum of two more identical monthly doses of Octreotide LAR (with an interval of 28 days between them), until first-line chemotherapy is discontinued or for a maximum of six doses of Octreotide LAR, whichever occurs first.

    Also known as: Octreotide LAR, Sandostatin LAR

  • OtherStandard Treatment

    Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Developing Diarrhea (Grade 1 to 4)

    The percentage of patients developing diarrhea (incidence of grade 1 to 4) during treatment, considering only the worst grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 0=None, 1 = Increase of \<4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence; or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse.

    Time frame: 6 month overall

Secondary outcomes

  1. Number of Episodes of Diarrhea by Patient

    Number of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis.

    Time frame: 6 months overall

  2. Number of Episodes of Diarrhea by Patient by Cycle

    Mean number of episodes of diarrhea is evaluated by patient diaries recorded by cycle. (cycle 1 to cycle 7.)

    Time frame: at each cycle (28 days per cycle)

  3. Percentage of Patients by Grade of Diarrhea

    Grade (severity) of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis by considering only worse grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 0 = None, 1 = Increase of \<4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence; or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse.

    Time frame: 6 months overall

  4. Percentage of Episodes by Grade

    Grade (severity)of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis by considering only worse grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 1 = Increase of \<4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence;or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse.

    Time frame: 6 months overall

  5. Percentage of Participants Who Need Chemotherapy Dose Reduction Due to Diarrhea

    For patient, chemotherapy dose reduction due to diarrhea as counted each time it occurred. Chemotherapy dose reduction because of other adverse events related to chemotherapy was not considered.

    Time frame: 6 months overall

  6. Percentage of Participants Who Need Opioids for Control of Diarrhea

    Time frame: 6 months overall

  7. Percentage of Patients Hospitalized Due to Diarrhea

    Time frame: 6 months overall

  8. Percentage of Participants Who Need Intravenous Hydration for Control of Diarrhea

    Time frame: 6 months overall

  9. Percentage of Participants With Complete or Partial Response at Response Evaluation Criteria in Solid Tumors (RECIST)

    Lesions that can be accurately measured in at least one dimension (longest diameter (LD) to be recorded) as \> 20 mm with conventional techniques (CT, MRI) or as \> 10 mm with spiral CT scan. All measurable lesions up to maximum of 5 lesions per organ and 10 lesions in total representative of all involved organs should be identified as target lesions and recorded and measured at baseline. Complete Response is defined as Disappearance of all target lesions. Partial Response is defined at least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD.

    Time frame: Day 56, Day 84, Day 112, Day 140, Day 168

  10. Change From Baseline in Quality of Life Measured by the Functional Assessment of Chronic Illness Therapy-Diarrhea (FACIT-D)

    Quality of life (QoL) is evaluated using FACIT-D scale. FACIT-D is composed of 38 items, whose responses range from 0 to 4. The total FACIT-D score may range from 0 to 152. The 38 items compose five subscales, each evaluating a different component of the (QOL). For calculating the subscale score, some items are computed in a reverse fashion, so that higher FACIT-D scores indicate a better (QoL). Descriptive statistics (mean, standard deviation, median, minimum and maximum) are used to summarize FACIT-D scores (total and subscales) by study group at each time point.

    Time frame: Baseline to Day 168

07

Results

Posted Mar 27, 2012
Limitations and caveats
Limitations were the small number of patients who received irinotecan and small proportion of patients with grade III and IV diarrhea. It is not possible to generalize our results for these populations. Study wasn't blinded or placebo-controlled.

Participant flow

Participant flow — Overall Study
MilestoneOctreotide Long Acting ReleaseStandard Treatment
Started6871
Completed4858
Not completed2013
Withdrew: Lost to follow-up02
Withdrew: Adverse event42
Withdrew: Protocol violation62
Withdrew: Death43
Withdrew: Withdrawal by subject32
Withdrew: Disease progression22
Withdrew: Use of illicit drugs10

Outcome measures

PrimaryPercentage of Participants Developing Diarrhea (Grade 1 to 4)

The percentage of patients developing diarrhea (incidence of grade 1 to 4) during treatment, considering only the worst grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 0=None, 1 = Increase of \<4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence; or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse.

Time frame:
6 month overall
Reported as:
Number · Percentage of Participants
Percentage of Participants Developing Diarrhea (Grade 1 to 4)
Percentage of ParticipantsOctreotide Long Acting ReleaseStandard Treatment
Percentage of Participants Developing Diarrhea (Grade 1 to 4)76.1 (64.7 to 84.7)78.9 (68 to 86.8)
SecondaryNumber of Episodes of Diarrhea by Patient

Number of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis.

Time frame:
6 months overall
Reported as:
Mean · Episodes/patients/day
Number of Episodes of Diarrhea by Patient
Episodes/patients/dayOctreotide Long Acting ReleaseStandard Treatment
Number of Episodes of Diarrhea by Patient21.6 ± 24.320.4 ± 19.6
SecondaryNumber of Episodes of Diarrhea by Patient by Cycle

Mean number of episodes of diarrhea is evaluated by patient diaries recorded by cycle. (cycle 1 to cycle 7.)

Time frame:
at each cycle (28 days per cycle)
Reported as:
Mean · Episodes/patient/cycle
Number of Episodes of Diarrhea by Patient by Cycle
Episodes/patient/cycleOctreotide Long Acting ReleaseStandard Treatment
Cycle 1 (n=20, 18)2.6 ± 2.22.2 ± 2
Cycle 2 (n=36,38)8.2 ± 6.85.9 ± 6.2
Cycle 3 (n=33,39)6.9 ± 7.86.7 ± 6.5
Cycle 4 (n=24, 27)8.6 ± 7.17.1 ± 7.1
Cycle 5 (n=20,29)8.1 ± 7.17 ± 8.8
Cycle 6 (n=22, 22)6.1 ± 6.95.8 ± 5.3
Cycle 7 (n= 16, 20)4.8 ± 6.36.6 ± 6.4
SecondaryPercentage of Patients by Grade of Diarrhea

Grade (severity) of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis by considering only worse grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 0 = None, 1 = Increase of \<4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence; or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse.

Time frame:
6 months overall
Reported as:
Number · Percentage of Participants
Percentage of Patients by Grade of Diarrhea
Percentage of ParticipantsOctreotide Long Acting ReleaseStandard Treatment
Grade 141.226.8
Grade 225.551.8
Grade 333.321.4
Grade 400
SecondaryPercentage of Episodes by Grade

Grade (severity)of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis by considering only worse grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 1 = Increase of \<4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence;or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse.

Time frame:
6 months overall
Reported as:
Number · Percentage of Episodes
Percentage of Episodes by Grade
Percentage of EpisodesOctreotide Long Acting ReleaseStandard Treatment
Grade 165.466.9
Grade 223.327.2
Grade 311.35.9
Grade 400
SecondaryPercentage of Participants Who Need Chemotherapy Dose Reduction Due to Diarrhea

For patient, chemotherapy dose reduction due to diarrhea as counted each time it occurred. Chemotherapy dose reduction because of other adverse events related to chemotherapy was not considered.

Time frame:
6 months overall
Reported as:
Number · Percentage of participants
Percentage of Participants Who Need Chemotherapy Dose Reduction Due to Diarrhea
Percentage of participantsOctreotide Long Acting ReleaseStandard Treatment
Percentage of Participants Who Need Chemotherapy Dose Reduction Due to Diarrhea26.9 (17.7 to 38.5)11.3 (5.8 to 20.7)
SecondaryPercentage of Participants Who Need Opioids for Control of Diarrhea
Time frame:
6 months overall
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Need Opioids for Control of Diarrhea
Percentage of ParticipantsOctreotide Long Acting ReleaseStandard Treatment
Percentage of Participants Who Need Opioids for Control of Diarrhea1.5 (0.3 to 8.0)1.4 (0.2 to 7.6)
SecondaryPercentage of Patients Hospitalized Due to Diarrhea
Time frame:
6 months overall
Reported as:
Number · Percentage of patients
Percentage of Patients Hospitalized Due to Diarrhea
Percentage of patientsOctreotide Long Acting ReleaseStandard Treatment
Percentage of Patients Hospitalized Due to Diarrhea64.2
SecondaryPercentage of Participants Who Need Intravenous Hydration for Control of Diarrhea
Time frame:
6 months overall
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Need Intravenous Hydration for Control of Diarrhea
Percentage of ParticipantsOctreotide Long Acting ReleaseStandard Treatment
Percentage of Participants Who Need Intravenous Hydration for Control of Diarrhea4.5 (1.5 to 12.4)7.0 (3.0 to 15.4)
SecondaryPercentage of Participants With Complete or Partial Response at Response Evaluation Criteria in Solid Tumors (RECIST)

Lesions that can be accurately measured in at least one dimension (longest diameter (LD) to be recorded) as \> 20 mm with conventional techniques (CT, MRI) or as \> 10 mm with spiral CT scan. All measurable lesions up to maximum of 5 lesions per organ and 10 lesions in total representative of all involved organs should be identified as target lesions and recorded and measured at baseline. Complete Response is defined as Disappearance of all target lesions. Partial Response is defined at least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD.

Time frame:
Day 56, Day 84, Day 112, Day 140, Day 168
Reported as:
Number · Percentage of Participants
Percentage of Participants With Complete or Partial Response at Response Evaluation Criteria in Solid Tumors (RECIST)
Percentage of ParticipantsOctreotide Long Acting ReleaseStandard Treatment
Day 56 (N=11,2)45.5 (21.3 to 72.0)0.0 (0.0 to 65.8)
Day 84 (N=5,3)60.0 (23.1 to 88.2)100 (43.8 to 100)
Day 112 (N=1,1)100 (20.7 to 100)0.0 (0.0 to 79.3)
Day 140 (N=9,1)44.4 (18.9 to 73.3)100 (20.7 to 100)
Day 168 (N=2,1)100 (34.2 to 100)100 (20.7 to 100)
SecondaryChange From Baseline in Quality of Life Measured by the Functional Assessment of Chronic Illness Therapy-Diarrhea (FACIT-D)

Quality of life (QoL) is evaluated using FACIT-D scale. FACIT-D is composed of 38 items, whose responses range from 0 to 4. The total FACIT-D score may range from 0 to 152. The 38 items compose five subscales, each evaluating a different component of the (QOL). For calculating the subscale score, some items are computed in a reverse fashion, so that higher FACIT-D scores indicate a better (QoL). Descriptive statistics (mean, standard deviation, median, minimum and maximum) are used to summarize FACIT-D scores (total and subscales) by study group at each time point.

Time frame:
Baseline to Day 168
Reported as:
Mean · Units on a scale
Change From Baseline in Quality of Life Measured by the Functional Assessment of Chronic Illness Therapy-Diarrhea (FACIT-D)
Units on a scaleOctreotide Long Acting ReleaseStandard Treatment
Change From Baseline in Quality of Life Measured by the Functional Assessment of Chronic Illness Therapy-Diarrhea (FACIT-D)0.5 ± 1.93.4 ± 2.0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Octreotide LAR—15/68 (22.1%)63/68 (92.6%)
Standard Treatment—14/71 (19.7%)68/71 (95.8%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventOctreotide LARStandard Treatment
DiarrhoeaGastrointestinal disorders5/684/71
AnaemiaBlood and lymphatic system disorders2/680/71
Gastrointestinal obstructGastrointestinal disorders2/682/71
MetastasisNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/680/71
PyelonephritisInfections and infestations0/682/71
PneumoniaRespiratory, thoracic and mediastinal disorders0/682/71
NauseaGastrointestinal disorders1/680/71
Mucosal inflammationGeneral disorders1/680/71
GastroenteritisInfections and infestations1/680/71
International normalisedInvestigations1/680/71
Most frequent other events
Showing 10 of 45
Most frequent other events
EventOctreotide LARStandard Treatment
DiarrhoeaGastrointestinal disorders54/6856/71
NauseaGastrointestinal disorders33/6846/71
Abdominal painGastrointestinal disorders19/6823/71
Neuropathy peripheralNervous system disorders18/6821/71
VomitingGastrointestinal disorders20/6816/71
MucositisGeneral disorders12/6820/71
Decreased appetiteMetabolism and nutrition disorders17/6814/71
NeutropeniaBlood and lymphatic system disorders11/6817/71
AnaemiaBlood and lymphatic system disorders15/6811/71
AstheniaGeneral disorders11/6812/71

Baseline characteristics

Age, Continuous
Age, Continuous(years)Octreotide Long Acting ReleaseStandard TreatmentTotal
Mean56.2 ± 12.855.5 ± 11.455.85 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Octreotide Long Acting ReleaseStandard TreatmentTotal
Female374178
Male313061
08

Study locations

11 sites
  • Biocâncer
    Belo Horizonte, Brazil
  • CEPON-Centro de Pesquisas Oncologicas
    Florianópolis, Brazil
  • Hospital Sao Lucas- Faculdade de Medicina da PUCRS
    Porto Alegre, Brazil
  • Clínica AMO
    Salvador, Brazil
  • Nucleo de Oncologia da Bahia
    Salvador, Brazil
  • Faculdade de Medicina do ABC
    Santo André, Brazil
  • Hosital Alemão Oswaldo Cruz
    São Paulo, Brazil
  • Hospital A C Camargo/ Fundação Antonio Prudente
    São Paulo, Brazil
  • Hospital das Clínicas - FMUSP
    São Paulo, Brazil
  • Instituto Arnaldo Vieira de Carvalho - IAVC
    São Paulo, Brazil
  • UNIFESP
    São Paulo, Brazil
09

References and documents

Publications

  • Hoff PM, Saragiotto DF, Barrios CH, del Giglio A, Coutinho AK, Andrade AC, Dutra C, Forones NM, Correa M, Portella Mdo S, Passos VQ, Chinen RN, van Eyll B. Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial. J Clin Oncol. 2014 Apr 1;32(10):1006-11. doi: 10.1200/JCO.2013.50.8077. Epub 2014 Feb 10. PubMed 24516038 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2007
First posted
Dec 28, 2007
Start
Apr 2008
Primary completionActual
Sep 2010
CompletionActual
Sep 2010
Results first posted
Mar 27, 2012
Last update
May 4, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00582426
Responsible party
Sponsor
First posted
Dec 28, 2007
Start date
Apr 2008
Primary completion
Sep 2010
Completion
Sep 2010
Results posted
Mar 27, 2012
Last update
May 4, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Octreotide

Start the discussion